Tahara et al. have reported that the SGLT2 inhibitor, ipragliflozin, reduced plasma and liver levels of oxidative stress biomarkers and inflammatory markers, and ameliorated hyperglycemia in a mouse model of diabetes [30]. Here, SLC5A2 is linked to Hyperglycemia.